reports
Pharming Group announces 2026 financial guidance and highlights rare d...
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:...
Pharming Group receives Complete Response Letter from U.S. FDA for sND...
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rar...
- Roy Külter
- Steven Boumans
ALFOC FOCUS HOME INTERACTIVE SA
LI KLEPIERRE SA
COV COVIVIO SA
GFC GECINA SA
NXI NEXITY SA CLASS A
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
INEA FONCIERE INEA
WHA WERELDHAVE N.V.
KCO KLOECKNER & CO SE
BLND BRITISH LAND COMPANY PLC
NRG NRJ GROUP SA
KOF KAUFMAN & BROAD SA
ALTA ALTAREA SCA
VNA VONOVIA SE
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
BYG BIG YELLOW GROUP PLC
UTG UNITE GROUP PLC
COFB COFINIMMO SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
CPINV CARE PROPERTY INVEST SA
SAFE SAFESTORE HOLDINGS PLC
ARG ARGAN SA
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
MEDCL MEDINCELL SA
AEDAS AEDAS HOMES SA
THEP THERMADOR HOLDING SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
ALAFY AFYREN
CTPNV CTP NV
LHYFE LHYFE S.A.
SHUR SHURGARD SELF STORAGE LIMITED
ALHG LOUIS HACHETTE GROUP
- Roy Külter
- Steven Boumans
ALFOC FOCUS HOME INTERACTIVE SA
LI KLEPIERRE SA
COV COVIVIO SA
GFC GECINA SA
NXI NEXITY SA CLASS A
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
INEA FONCIERE INEA
WHA WERELDHAVE N.V.
KCO KLOECKNER & CO SE
BLND BRITISH LAND COMPANY PLC
NRG NRJ GROUP SA
KOF KAUFMAN & BROAD SA
ALTA ALTAREA SCA
VNA VONOVIA SE
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
BYG BIG YELLOW GROUP PLC
UTG UNITE GROUP PLC
COFB COFINIMMO SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
CPINV CARE PROPERTY INVEST SA
SAFE SAFESTORE HOLDINGS PLC
ARG ARGAN SA
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
MEDCL MEDINCELL SA
AEDAS AEDAS HOMES SA
THEP THERMADOR HOLDING SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
ALAFY AFYREN
CTPNV CTP NV
LHYFE LHYFE S.A.
SHUR SHURGARD SELF STORAGE LIMITED
ALHG LOUIS HACHETTE GROUP
- Jeremy Garnier
- Jeremy Garnier
Pharming Group reports preliminary 2025 revenues and announces Investo...
Pharming Group reports preliminary 2025 revenues and announces Investor Day Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET). Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2...
- Baptiste Lebacq
- Christophe-Raphaël Ganet
- Emmanuel Matot
- Thomas Zlowodzki
GTT GAZTRANSPORT & TECHNIGAZ SA
P2F PETROFAC LIMITED
SAVE SAVENCIA SA
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
ROYAL VOPAK NV
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
FNTN FREENET AG
TRE TECNICAS REUNIDAS SA
TEC TECHNIPFMC PLC
SAE SHOP APOTHEKE EUROPE NV
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
VK VALLOUREC SA
TE TECHNIP ENERGIES NV
SPM SAIPEM S.P.A.
TEN TENARIS S.A.
PLX PLUXEE NV
VIRI VIRIDIEN
LOUP SOCIETE L.D.C.
- Baptiste Lebacq
- Christophe-Raphaël Ganet
- Emmanuel Matot
- Thomas Zlowodzki
BEKB BEKAERT SA
SLB.N SCHLUMBERGER NV
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
P2F PETROFAC LIMITED
SAVE SAVENCIA SA
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
NDA AURUBIS AG
ROYAL VOPAK NV
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
FNTN FREENET AG
TRE TECNICAS REUNIDAS SA
RIO RIO TINTO PLC
TEC TECHNIPFMC PLC
SAE SHOP APOTHEKE EUROPE NV
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
VK VALLOUREC SA
VUL VULCAN ENERGY RESOURCES
TE TECHNIP ENERGIES NV
SPM SAIPEM S.P.A.
TEN TENARIS S.A.
PLX PLUXEE NV
VIRI VIRIDIEN
LOUP SOCIETE L.D.C.
AAL ANGLO AMERICAN PLC
- Jeremy Garnier
- Jeremy Garnier
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Jeremy Garnier
- Jeremy Garnier
Pharming Group NV: 1 director
A director at Pharming Group NV sold 90,691 shares at 1.500EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Pharming Group reports third quarter 2025 financial results with signi...
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for c...
Pharming Group announces presentations at 2025 ACAAI Annual Scientific...
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10. Five posters will present positive new clinical, economic, and comparative data for RUCONEST® (recombinant C1 esterase inhibi...
Pharming Group provides update on previously announced G&A expense red...
Pharming Group provides update on previously announced G&A expense reduction plan Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reduction in non-com...
Pharming Group announces U.S. FDA acceptance and Priority Review of su...
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from multinational Phase III study in children aged 4 to 11 years with APDSPDUFA target action date of January 31, 2026 Leiden, the Netherlands, October 1, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.